Nyxoah says U.S. Pivotal Study meets primary safety, efficacy endpoints
Nyxoah SA said its U.S. Pivotal Study met the primary safety and efficacy endpoints in complete concentric collapse patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.